Advances in the Surgical Treatment of Neuroblastoma

Yan-Bing Luo, Xi-Chun Cui, Lin Yang, Da Zhang, Jia-Xiang Wang
Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan 450052, China

Abstract

Objective: This study was to review the efficacy of surgical resections in different clinical situations for a better understanding of the meaning of surgery in the treatment of neuroblastoma (NB).

Data Sources: The online database ScienceDirect (2016–2018) was utilized. The search was conducted using the keywords “neuroblastoma,” “neuroblastoma resection,” “neuroblastoma surgery,” and “high-risk neuroblastoma.”

Study Selection: We retrospectively analyzed of patients who underwent surgical resections in different clinical situations. The article included findings from selected relevant randomized controlled trials, systematic reviews, and meta-analyses or good-quality observational studies. Abstracts only, letters, and editorial notes were excluded. Full-text articles and abstracts were extracted and reviewed to identify key articles discussing surgery management of NB, which were then selected for critical analysis.

Results: A total of 7800 English language articles were found containing references to NB (2016–2018). The 163 articles were searched which were related to the surgical treatment of NB (2016–2018). Through the analysis of these important articles, we found that the treatments of NB at low- and intermediate-risk groups were basically the same. High-risk patients remained controversial.

Conclusions: NB prognosis varies tremendously based on the stage and biologic features of the tumor. After reviewing the relevant literature, patients with low-risk disease are often managed with surgical resection or observation alone with tumors likely to spontaneously regress that are not causing symptoms. Intermediate patients are treated with chemotherapy with the number of cycles depending on their response as well as surgical resection of the primary tumor. High-risk patients remain controversial. Multidisciplinary intensive treatment is essential, especially for patients who received subtotal tumor resection. Minimally invasive surgery for the treatment of NBs without image-defined risk factors in low- to high-risk patients is safe and feasible and does not compromise the treatment outcome. We conclude that ≥90% resection of the primary tumor is both feasible and safe in most patients with high-risk NB. New targeted therapies are crucial to improve survival.

Key words: Advance; High Risk; Neuroblastoma Surgical Resection; Survival

INTRODUCTION

Neuroblastoma (NB) is the most common extracranial solid tumor in children, arising from neural crest cells that differentiate to the sympathetic ganglia and adrenal medulla.[1,2] The occurrence of NB is unusual in adolescents and adults.[3] Metastatic NB in children older than one year is still associated with a poor prognosis, as the majority of these patients, after an initial response to chemotherapy, suffer relapse of drug-resistant disease. Staging is performed using bone marrow and mIBG scan. Age, stage, histopathological grading, MYCN amplification, and 11q aberration are important prognostic factors utilized in risk stratification.[4,5] Timing and choice of treatment modalities varies according to the stage, location of tumor, associated risk factors, and patient’s age. A surgical resection is the mainstay of treatment for a localized tumor. Patients with low- and intermediate-risk NB have an estimated overall survival (OS) rate over 90% with an ongoing trend toward minimization of therapy.[6] However, high-risk disease has a suboptimal outcome, though the survival is improving with multimodality therapy including autologous stem-cell transplant and immunotherapy. Relapse after multimodality...
Magnetic resonance imaging is preferred in poorer outcomes are associated with deletions at the to predict NB outcome. Aggressive tumor behaviors with together with tumor cell DNA content, have been shown MYCN stages. However, almost 80% of NBs harbor nonamplified in patients at all ages, infants included, and at all tumor amplification (more than 10 copies per cell) is strongly metabolic changes in cancer cells. MYCN is correlated with advanced stage, unfavorable tumor biology and poor outcome even in infants and lower stages. Cancer cells reprogram their metabolism to survive, grow, and proliferate. MYCN is the underlying cause of metabolic changes in cancer cells. In NB, a MYCN amplification (more than 10 copies per cell) is strongly associated with rapid disease progression and poor outcome in patients at all ages, infants included, and at all tumor stages. However, almost 80% of NBs harbor nonamplified MYCN. Several other somatically acquired chromosomal aberrations associated with DNA copy number alterations, together with tumor cell DNA content, have been shown to predict NB outcome. Aggressive tumor behaviors with poorer outcomes are associated with deletions at the chromosomal region 1p36.3 or 11q23. MYC oncoproteins are transcription factors which may cause deregulated tumor growth on overexpression. Therefore, many efforts have been made in developing suitable MYCN drug that could impair its functions, and the same attempts are still ongoing. This is because of difficulties in developing an optimal therapy against MYCN due to a lack of appropriate surfaces on its DNA-binding domain to which drugs can bind. This problem persists not only for MYCN but also for other Myc family members. Therefore, at present, a more widely accepted approach for MYCN regulation involves its indirect targeting.

**Clinical Features**

Clinical presentation of NB varies widely by age and stage. Survival remains poor with greater than 50% of children having widespread metastatic disease at initial clinical presentation. The location of the primary tumor and any metastatic sites dictates the symptomatology. It is a highly malignant tumor comprising undifferentiated and differentiating cells originating from neural crest-derived sympathoadrenal precursors. NB can originate from anywhere along the sympathetic chain, presenting as a mass arising in the neck, mediastinum, abdomen, or pelvis. Cases have been detected antenatally, during ultrasound examination, and some of these patients, together with those diagnosed in the 1st day of life, have been observed to undergo spontaneous regression. Hypertension is common and managed with oral antihypertensives, typically resolving with surgical resection/chemoreduction of the tumor. Although not specific markers for neuroblastoma - high levels at diagnosis of serum markers ferritin (more than 142 ng/ml), neuron specific enolase (NSE, more than 100 ng/ml), and lactate dehydrogenase (LDH, more than 1500 IU/L) have been shown to be predictive of poorer outcome. High-performance liquid chromatography has a sensitivity/specificity as close to 100%. Random/spot urine samples are as effective as 24-h collections and more practical.

Tumors often infiltrate local structures and surround nerves or vital vessels such as the celiac artery axis. Tumors typically metastasize to regional lymph nodes and bone marrow.

**MYCN Oncogene**

MYCN is correlated with advanced stage, unfavorable tumor biology and poor outcome even in infants and lower stages. Cancer cells reprogram their metabolism to survive, grow, and proliferate. MYCN is the underlying cause of metabolic changes in cancer cells. In NB, a MYCN amplification (more than 10 copies per cell) is strongly associated with rapid disease progression and poor outcome in patients at all ages, infants included, and at all tumor stages. However, almost 80% of NBs harbor nonamplified MYCN. Several other somatically acquired chromosomal aberrations associated with DNA copy number alterations, together with tumor cell DNA content, have been shown to predict NB outcome. Aggressive tumor behaviors with poorer outcomes are associated with deletions at the chromosomal region 1p36.3 or 11q23. MYC oncoproteins are transcription factors which may cause deregulated tumor growth on overexpression. Therefore, many efforts have been made in developing suitable MYCN drug that could impair its functions, and the same attempts are still ongoing. This is because of difficulties in developing an optimal therapy against MYCN due to a lack of appropriate surfaces on its DNA-binding domain to which drugs can bind. This problem persists not only for MYCN but also for other Myc family members. Therefore, at present, a more widely accepted approach for MYCN regulation involves its indirect targeting.

**Diagnosis**

**Biopsy**

Biopsy of the tumor confirms the diagnosis and provides important information on prognosis. Open surgical biopsy has been traditionally deployed in many centers worldwide, but minimally invasive image-guided biopsy is also highly efficient at tumor diagnosis and has decreased complication rates. Multiple bone marrow biopsies and aspirates are also taken at diagnosis to stage metastases. An unequivocal pathological diagnosis from tumor tissue is made by light microscopy, with or without immunohistochemistry (IHC) or raised urine/serum homovanillic acid (HVA) or vanillylmandelic acid (VMA). IHC aids in distinguishing NBL from other small round blue cell tumors. The VMA/HVA ratio has also been shown to provide additional information. A study reported that percutaneous core needle biopsy is adequate for complete tissue diagnosis of NB and can be safely performed. This can be considered as an alternative to open surgical biopsy.

**Radiological Staging**

Radiological staging of the primary tumor is commonly performed with a contrast-enhanced computed tomography scan. Magnetic resonance imaging is preferred in paraspinal lesions. Metastatic evaluation classically includes bilateral bone marrow aspirate and trephine and a mIBG scan. mIBG is the most sensitive metastatic investigation for skeletal/soft tissue. Re-evaluation following chemotherapy is recommended with mIBG or fluorodeoxyglucose–positron emission tomography (FDG-PET). A bone scan is not reliable for re-evaluation. In a recent study, FDG-PET was superior to mIBG for detection of lymph nodal and bone/bone marrow lesions.

**Risk Stratification**

The traditional International Neuroblastoma Staging System (INSS) categorizes the tumors into four stages, based on the extent of surgical resection. The associated risk stratification schema classifies tumors into low, intermediate, and high risk, depending on the stage of the tumor, as well as whether the tumor exhibits amplification of the MYCN gene and has favorable histologic features. The International Neuroblastoma Risk Group (INRG) system stratifies risk
into four groups – very low, low, intermediate, and high depending on MYCN amplification (high risk), stage, and biological features. The INRG staging system evolved based on presurgical radiology and metastatic status.[17,18] In this system, nonmetastatic tumors are assessed for surgical risk factors that predict unresectability using radiographic imaging, known as image-defined risk factors (IDRFs). Variables utilized for risk stratification include age, stage, histopathological grading, serum LDH, serum ferritin, DNA ploidy, MYCN gene amplification status, and segmental chromosomal aberrations.[9,13,18] The original Shimada pathological classification has been replaced by the more comprehensive International Neuroblastoma Pathological Classification (INPC) system. The new INPC system is based on age at diagnosis, mitosis-karyorrhexis index (MI), neuroblastic differentiation, and stromal content. INPC has a proven role in predicting outcome. The system classifies tumors as favorable/unfavorable based on age, differentiation, maturation, Schwannian stroma, and MKI. The International Society of Pediatric Oncology (SIOP) guideline encourages INPC whenever expertise is available. Patients with Stage 4 disease in the age group of 12–18 months are considered high risk, if the tumor is classified unfavorable by INPC and/or diploidy/hypodiploidy (even if MYCN nonamplified). In a study, the polymorphism rs1800795 is associated with serum interleukin-6 level and level of NB risk. Genotype might indicate that the tumor is highly malignant (prone to metastasis) and associated with poor prognosis.[19] These risk stratifications help in understanding the amount that each risk factor contributes to survival in a way that separate survival curves cannot.

Treatment

Treatment strategies are guided by the Children’s Oncology Group (COG) risk stratification as low-, intermediate- and high-risk groups. The various modalities deployed in the treatment of NB include surgery, chemotherapy, radiotherapy, differentiation therapy, immunotherapy, and in selected cases careful observation only. Surgical resection alone has proven to be curative for most patients with low-risk NB with 5-year OS of 97%. Because antibody therapy seems most effective against bone marrow and not soft-tissue masses, its use might unmask a positive effect of resection on outcome. Antibody therapy has been shown to improve event-free survival (EFS) and OS in high-risk NB.[20] Alternatively, improved survival might obscure any clinically apparent effect of resection.

Low-risk neuroblastoma

Low-risk disease including Stage 1 and asymptomatic Stage 2 disease has an excellent prognosis with nonmutating surgery alone. The 3-year OS in this group approaches 97%.[13] The goal has been to decrease therapy for low-risk patients to avoid long-term complications while augmenting and targeting therapies for high-risk patients to improve OS.[21] Perinatal adrenal NB maybe managed with close observation alone, unless there are life- or organ-threatening symptoms at diagnosis. Treatment for asymptomatic low-risk patients with an estimated survival of >98% is often observation or surgical resection alone.

Intermediate-risk neuroblastoma

Patients with “intermediate-risk” group tumors which are not amenable for primary resection receive chemotherapy to halt rapid tumor progression, treat life-threatening symptoms, or improve tumor resectability. Chemotherapy (4–8 cycles) for debulking and metastatic remission, followed by surgery aiming at maximum safe resection (residual tumor need not cause concern), is the recommended approach. If metastases are in remission and primary tumor has responded by >50%, a judicial resection can be done, with no further chemotherapy.[13] If such a response has not been achieved, resection is attempted following administration of additional four cycles of chemotherapy. Patients with intermediate-risk NB with or without postchemotherapy residual tumor resection had an excellent long-term outcome. However, patients with intermediate-risk NB with or without postchemotherapy residual tumor resection had an excellent long-term outcome.[22] The extent of resection does not affect the survival and complications can occur even when the resection is incomplete.[23] Therefore, aggressive attempts at complete resection are unnecessary, as the biology here favors differentiation rather than progression and can lead to life-threatening complications. There was no difference in OS or EFS among the patients with complete resection, minimal residual disease, or biopsy only.[24] Very high proportions of survival are currently achievable in patients with intermediate-risk NB.

High-risk neuroblastoma

Treatment strategies of high-risk neuroblastoma are guided by the Children's Oncology Group (COG) based on age, International Neuroblastoma Staging System (INSS) stage, and tumor biology notably International Neuroblastoma Pathology Classification system (INPC), amplification of N-myc proto-oncogene and DNA ploidy. Literature available at the present time were all nonrandomized observational studies with much study heterogeneity owing to variable treatment protocols and chemotherapy regimens in different institutions.[7] High-risk NB patients who receive four cycles of chemotherapy before surgical resection have a superior OS than patients who receive 2.[25] However, the 5-year OS rate of high-risk patients remains around 40–50%.[18] Patients diagnosed with high-risk factors often have poor prognoses.

The role of surgical resection of the primary tumor in high-risk NB is controversial with conflicting studies in the literature regarding the benefit of aggressive surgery.[26] Study results indicate that local treatment with gross total resection” (GTR)/subtotal resection (STR) with local irradiation may be safe and sufficient for preventing local recurrence in INSS 4 NB patients who received “delayed local treatment.” Rich BS reported that a gross total resection is possible in high-risk patients with IDRFs without increasing morbidity.[27] In addition, we reviewed other literature. We
conclude that ≥90% resection is both feasible and safe in most patients with high-risk NB. Hence, the treatment strategy may have advantages in terms of surgical invasiveness and the rates of postoperative complications and recurrence. Nevertheless, other studies showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients who received STR. Long-term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy. The outcome for patients with NB has improved; however, the field continues to expand efforts in more targeted therapies for high-risk patients.

**Surgery**

**Extent of resection**

Surgery has an important role both at the time of diagnosis and during treatment. NB has an elevated tropism for lymphatic vessels and lymph node infiltration; surgical tumor resection should include exploration of locoregional lymph nodes, especially in abdominal and pelvic locations. Surgical resection aims to achieve macroscopic tumor resection with minimal residual disease. In other cases, when the features of the tumor (site, size, and relationship with surrounding structures) indicate that surgical resection is not feasible without risk, surgery is limited to providing enough tumor tissue to make the histological diagnosis and to carry out biologic studies. If one or more of these features have been documented, presurgical chemotherapy should be administered to shrink the tumor and enable safe tumor resection. Such as paravertebral locations with spinal canal invasion through intervertebral foramina, laminectomy is indicated only in the presence of rapidly progressive neurological symptoms, as chemotherapy can rapidly reduce the volume of the tumor and relieve compression. Complete resection can be difficult to attain in this disease because of primary tumor encasement of nerves and blood vessels and frequent regional lymph node involvement. In addition, metastases to bone, bone marrow, distant lymph nodes, and other sites are unaffected by primary tumor resection. Maximum tumor resection with as much preservation of organ/neurologic function as possible is attempted postinduction chemotherapy. Although the greatest impact of resection should be on local control, some researchers argue in favor of GTR. A meta-analysis showed a survival benefit for GTR in Stage 3, while GTR did not significantly improve OS in Stage 4 disease. For patients, high-risk NB remains controversial. Recent prospective data from both COG and International Society of Pediatric Oncology Europe-Neuroblastoma (SIOPEN) support more complete resection in high-risk patients. However, given the high incidence of local relapses, the current indication in the majority of treatment protocols is resection of the primary tumor after debulking at metastatic sites. In contrast with its pivotal role in local disease, surgery has a somewhat controversial role in metastatic disease. von Allmen et al. found poor concordance between the assessment of resection extent by the operating surgeons and assessment through central imaging review. Despite discordance between clinical assessment of resection extent and assessment through central imaging review, a surgeon-assessed resection extent ≥90% was associated with significantly better EFS. Improving OS, however, remains a challenge in this disease.

Minimally invasive surgery (MIS) has gained popularity in pediatric oncology, and recent results have suggested the safety and effectiveness of this approach when IDRFs are absent. A study showed that laparoscopic adrenalectomy was safe, and among patients who met selection criteria for this procedure, there was no difference in mortality or recurrence rates between high-risk and low/intermediate-risk patients. These results suggest that MIS is indicated for the resection of selected NBs without IDRFs, while open surgery should be preferred if vascular control is considered difficult or complete tumor resection uncertain or risky. In addition, MIS for the treatment of NBs without IDRFs in low- to high-risk patients is safe and feasible and does not compromise the treatment outcome.

**Complications**

Surgeons should always consider the efficacy of a tumor resection, while also considering the occurrence of possible surgical complications. The basic principles of surgical resection include the accurate and safe display of vital vascular anatomy with the optimal exposure of the tumor to achieve gross resection. Indeed, the effect of primary tumor resection has not been included as a specific aim in any reported cooperative group studies until a recent analysis by the SIOPEN. The international has recently identified several imaging features (IDRFs) potentially associated with surgery-related complications. IDRFs include tumor extension into a second body compartment, encasement of any large blood vessels, tracheal or large bronchial compression, involvement of major nerve roots (such as the brachial plexus), invasion of the spinal canal, or infiltration of the nearby kidneys, mesentery, pericardium, liver, diaphragm, or pancreas. These are predictive of worse event-free and OS. The preservation of vital organs or vessels should be more important in high-risk patients in the era of intense chemotherapy and radiotherapy. The attempt at tumor resection in the presence of IDRFs lowers the chance of complete resection rate and implies greater risk of surgery-related complications. No significant difference in the proportion of patients with a complication was detected between the <90% and ≥90% resection. Hence, the complication rate was not increased in patients who underwent more extensive surgery. However, the complications induced by intense chemotherapy and radiotherapy have not been clearly elucidated. Future long-term follow-up studies of chemotherapy- or radiotherapy-related complications such as growth retardation, hearing impairment, infertility, endocrine dysfunction, and most importantly second
cancer will reclarify the role of surgery in the treatment of NB. [39]

OUTLOOK
Over the years, the outcome of patients with NBL has improved more slowly than that of patients with other childhood tumors. In the last decade, however, fruitful preclinical research has yielded many insights into the biology of NBL. The recent technological developments discussed above will certainly contribute to increase further our knowledge of these tumors and may enable us to identify the molecular aberrations and the cellular networks leading to tumor initiation and progression in each individual patient. Furthermore, access to an increasing number of actionable drugs now offers the possibility to develop new clinical trials. Together with this change in the approach for forthcoming clinical trials, a strengthening of international expert collaboration will enforce the development of clinical and biological studies and will speed the application of precision medicine for children diagnosed with NBL. In this way, precision medicine could finally be directed toward increasing survival rates and improving the quality of life of patients with NBL.

CONCLUSION
NB is a challenging disease for pediatric cancer specialists and surgeons. Surgery plays a role in the diagnosis and management of all stages of NB. NB being a highly infiltrative tumor presents many challenges for the surgeon as it is not usually possible to get microscopically negative resection margins where gross resection (GTR) is desirable. The role for surgery in localized, low-risk NB remains clearly defined, as gross total resection can be curative in these patients. However, the role of surgery greatly varies according to the clinical situation. The extent of resection, in high-risk NB, continues to evolve. Much of these data, however, come from retrospective studies, and prospective surgical studies are needed to further define the importance of surgical resection in intermediate- and high-risk patients.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Gajjar A, Packer R, Foreman N, Cohen K, Haas-Kogan D, Merchant T, et al. Children’s oncology group’s 2013 blueprint for research: Central nervous system tumors. Pediatric Blood Cancer 2013;60:979-84. doi: 10.1002/pbc.24433.

2. Monclair T, Mosseri V, Cecchetto G, De Bernardi B, Michon J, Holmes K, et al. Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group. Pediatr Blood Cancer 2015;62:1536-42. doi: 10.1002/pbc.25460.

3. Gatta G, Ferrari A, Stiller CA, Pastore G, Bisognog G, Trama A, et al. Embryonal cancers in Europe. Eur J Cancer 2012;48:1425-33. doi: 10.1016/j.ejca.2011.12.027.

4. Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, et al. Management of neuroblastoma: ICMR consensus document. Indian J Pediatr 2017;84:456-64. doi: 10.1007/s12098-017-2298-0.

5. Irwin MS, Park JR. Neuroblastoma: Paradigm for precision medicine. Pediatr Clin North Am 2015;62:225-56. doi: 10.1016/j.pcl.2014.09.015.

6. Ahmed G, Fawzy M, Elmenawi S, Elzomor H, Yosif Y, Elkinaai N, et al. Role of surgery in localized initially unresectable neuroblastoma. J Pediatr Surg 2018;14:231-6. doi: 10.1016/j.jpedsurg.2018.03.008.

7. Mullassyess D, Famelly P, Loatly PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatr Hematol Oncol 2014;37:1008-9. doi: 10.3109/08880018.2014.947009.

8. Vo KT, Matthay KK, Neuhau J, London WB, Hero B, Ambros PF, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: A report from the international neuroblastoma risk group project. J Clin Oncol 2014;32:3169-76. doi: 10.1200/JCO.2014.56.1.21.

9. Park JK, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65-86. doi: 10.1016/j.hoc.2009.11.011.

10. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016;2:e1600200. doi: 10.1126/sciadv.1600200.

11. Prochownik EV, Vogt PK. Therapeutic targeting of myc. Genes Cancer 2010;1:650-9. doi: 10.1177/1947606910377494.

12. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010;293:144-57. doi: 10.1016/j.canlet.2010.01.015.

13. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas A, et al. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low – And middle-income settings. Pediatr Blood Cancer 2015;62:1305-16. doi: 10.1002/pbc.25501.

14. Campagna G, Rosenberg F, Foster J, Vasudevan S, Nuchtern J, Kim E, et al. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg 2018. pii: S0022-3468(18)30252-5. doi: 10.1016/j.jpedsurg.2018.04.012.

15. Vassiliou V, Polvyiou P, Andreopoulos D, Frangos S, Kardamakis D. Bone metastases: Assessment of therapeutic response using radiological and nuclear medicine imaging modalities. Clin Oncol 2011;23:632-45. doi: 10.1016/j.clon.2011.03.010.

16. Dhill VS, Sharma P, Patel C, Kundu P, Agarwal S, Bakhishi S, et al. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: Comparison with 111I-MIBG scintigraphy. Nucl Med Commun 2015;36:1007-13. doi: 10.1097/NMN.0000000000000347.

17. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The international neuroblastoma risk group (INRG) staging system: An INRG task force report. J Clin Oncol 2009;27:298-303. doi: 10.1200/JCO.2008.16.6876.

18. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 2015;33:3008-17. doi: 10.1200/JCO.2014.59.4648.

19. Zhao Q, Jin M, Zhang DW, Zhao W, Wang XS, Yue ZX, et al. Serum interleukin-6 level and the rs1800795 polymorphism in its gene associated with neuroblastoma risk in Chinese children. Chin Med J 2018;131:1075-8. doi: 10.4103/0366-6999.230719.

20. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34. doi: 10.1056/NEJMoa0911123.

21. Tolbert VP, Matthay KK. Neuroblastoma: Clinical and biological approach to risk stratification and treatment. Cell Tissue Res 2018;372:195-209. doi: 10.1007/s00441-018-2821-2.

22. Amano H, Uchida H, Tanaka Y, Tainaka T, Mori M, Oguma E, et al. Excellent prognostic patients of children with intermediate-risk neuroblastoma and residual tumor postchemotherapy. J Pediatr Surg 2017. pii: S0022-3468(17)30718-2. doi: 10.1016/j.jpedsurg.2017.10.061.

23. Qureshi SS, Bhagat M, Harris C, Chinnaswamy G, Vora T, Kembhavi S, et al. Outcomes and complications of surgery in patients with intermediate-risk neuroblastoma: Experience from an Indian tertiary cancer centre. Pediatr Surg Int 2018;34:435-42. doi: 10.1007/s00383-018-4241-5.
24. Kohler JA, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study. Eur J Cancer 2013;49:3671-9. doi: 10.1016/j.ejca.2013.07.002.

25. Rojas Y, Jaramillo S, Lyons K, Mahmood N, Wu MF, Liu H, et al. The optimal timing of surgical resection in high-risk neuroblastoma. J Pediatr Surg 2016;51:1665-9. doi: 10.1016/j.jpedsurg.2016.05.021.

26. De Ioris MA, Crocoli A, Contoli B, Garganese MC, Natali G, Tonà P, et al. Local control in metastatic neuroblastoma in children over 1 year of age. BMC Cancer 2015;15:79. doi: 10.1186/s12885-015-1082-7.

27. Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, et al. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011;46:103-7. doi: 10.1016/j.jpedsurg.2010.09.075.

28. von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, et al. Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol 2017;35:208-16. doi: 10.1200/JCO.2016.67.2642.

29. Uehara S, Yoneda A, Oue T, Nakahata K, Zenitani M, Miyamura T, et al. Role of surgery in delayed local treatment for INSS 4 neuroblastoma. Pediatr Int 2017;59:986-90. doi: 10.1111/ped.13349.

30. Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, et al. A single center clinical analysis of children with high-risk neuroblastoma. Oncotarget 2017;8:30357-68. doi: 10.18632/oncotarget.15996.

31. Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP, et al. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg 2011;21:314-7. doi: 10.1055/s-0031-1280824.

32. Lim II, Goldman DA, Farber BA, Murphy JM, Abramson SJ, Basu E, et al. Image-defined risk factors for nephrectomy in patients undergoing neuroblastoma resection. J Pediatr Surg 2016;51:975-80. doi: 10.1016/j.jpedsurg.2016.02.069.

33. De Bernardi B, Quaglietta L, Haupt R, Castellano A, Tirtei E, Luksch R, et al. Neuroblastoma with symptomatic epidural compression in the infant: The AIEOP experience. Pediatr Blood Cancer 2014;61:1369-75. doi: 10.1002/pbc.25028.

34. La Quaglia MP. The role of primary tumor resection in neuroblastoma: When and how much? Pediatr Blood Cancer 2015;62:1516-7. doi: 10.1002/pbc.25585.

35. Yeung F, Chung PH, Tam PK, Wong KK. Is complete resection of high-risk stage IV neuroblastoma associated with better survival? J Pediatr Surg 2015;50:2107-11. doi: 10.1016/j.jpedsurg.2015.08.038.

36. Shirota C, Tainaka T, Uchida H, Hinoki A, Chiba K, Tanaka Y, et al. Laparoscopic resection of neuroblastomas in low – To high-risk patients without image-defined risk factors is safe and feasible. BMC Pediatr 2017;17:71. doi: 10.1186/s12887-017-0826-8.

37. Kelleher CM, Smithson L, Nguyen LL, Casadiego G, Nasr A, Irwin MS, et al. Clinical outcomes in children with adrenal neuroblastoma undergoing open versus laparoscopic adrenalectomy. J Pediatr Surg 2013;48:1727-32. doi: 10.1016/j.jpedsurg.2013.03.056.

38. Luksch R, Castellani MR, Collini P, De Bernardi B, Conte M, Gambini C, et al. Neuroblastoma (Peripheral neuroblastic tumours). Crit Rev Oncol Hematol 2016;107:163-81. doi: 10.1016/j.critrevonc.2016.10.001.

39. Kubota M. The role of surgery in the treatment of neuroblastoma. Surg Today 2010;40:526-32. doi: 10.1007/s00595-009-4092-8.

40. Warmann SW, Seitz G, Schaefer JF, Scheel-Walter HG, Leuschner I, Fuchs J, et al. Vascular encasement as element of risk stratification in abdominal neuroblastoma. Surg Oncol 2011;20:231-5. doi: 10.1016/j.suron.2010.01.003.
神经母细胞瘤外科治疗进展

背景：在过去的几年中，神经母细胞瘤（NBL）手术治疗已经取得了一些进展，并对局部神经母细胞瘤手术治疗的作用进行了一些研究，但手术时机和原发肿瘤切除范围对高危患者预后的效果仍存在争议。本文回顾了手术切除在不同临床情况下的疗效，以便更好地理解手术治疗在神经母细胞瘤治疗中的意义。

数据资料：在ScienceDirect数据库中，我们通过使用关键词“神经母细胞瘤”、“神经母细胞瘤切除术”、“神经母细胞瘤手术”和“高危组神经母细胞瘤”检索从2016年到2018年有关神经母细胞的文章。

研究选择：我们回顾性分析了在不同临床情况下接受手术切除的患者。这些文章包括相关的随机对照试验，综述和meta分析和高质量的报告研究。只有摘要和编辑注释的文献被排除在外，我们回顾性分析与NBL外科治疗有关的含全文文章和摘要的文献。

结果：共检索到7800篇有关神经母细胞瘤的文献（2016～2018年）。检索到163篇与神经母细胞瘤外科治疗相关的文献（2016～2018）。通过分析这些重要文献，我们发现低中危神经母细胞瘤的治疗基本相同。但是高危患者仍存在争议。

结论：神经母细胞瘤的预后根据肿瘤的分期和生物学特征而有很大差异。在回顾相关文献后，低危患者通常通过手术切除或仅仅随访观察，肿瘤可能自发地消退而不会引起症状。中危患者接受化疗的周期取决于原发肿瘤的手术切除的效果。高危患者治疗仍存在争议。多学科强化治疗是必不可少的，尤其是对于接受次全切除术的患者。如果IDRFs评估没有风险因素，对于低中危患儿，微创手术是安全可行的。我们发现，在大多数高危神经母细胞瘤患者中，90%以上切除是可行的和安全的。新的治疗目标是提高患者生存率。